Partner Headlines - AMGN

  1. Health Care Sector Delivers Healthy Q1 Results

    IBD
  2. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  3. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  4. The Best And Worst ETFs Of The Week Amid Biotech Rebound

    Benzinga
  5. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  6. Crouching Tigers, Hidden Assets - Smead Capital Management

    GuruFocus
  7. Amgen's Decline Could Be A Good Thing

    Benzinga
  8. Should Amgen's T-Vec Results Be Questioned?

    Benzinga
  9. Amgen drug misses fast track

    IBD
  10. Why Baird Is Upgrading DaVita Healthcare

    Benzinga
  11. Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm

    IBD
  12. Amgen Reports An Upbeat Q1 Earnings

    GuruFocus
  13. Stocks Strengthen; Tesla Motors Rises On Battery News

    IBD
  14. Stocks Mildly Higher; China Nods To Visa, MasterCard

    IBD
  15. Amgen, Illumina Crush Views

    IBD
  16. Amgen, Illumina Earnings Hot, Intuitive Surgical Not

    IBD
  17. Amgen Tops Q1 Expectations, Shares Gain

    Benzinga
  18. Strategist: Amgen To Move 3% On Q1 Earnings News

    Benzinga
  19. What The Street...And The Crowd Are Watching At Amgen Before ...

    Benzinga
  20. Amgen Inc.'s First Quarter Earnings Preview - What Could Be In ...

    GuruFocus
  21. 5 Biotech Earnings Under The Microscope This Week

    Benzinga
  22. Amgen's First Drug For Cardiovascular Disease Gets The Green ...

    GuruFocus
  23. Why Amgen Might Start To Turn Around

    Benzinga
  24. Amgen Has A Big Launch Coming Up

    Benzinga
  25. AMGEN

    IBD
  26. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD
  27. Short Sellers Come Back To Biotech Stocks

    Benzinga
  28. Making Money With Charles Payne: 02/25/15

    FoxBusiness
  29. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  30. A Look At Dan Loeb's Diversified 13F

    Benzinga
  31. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  32. Short Sellers Retreat From Biotech Stocks

    Benzinga
  33. FDA Advisory Committee To Review Amgen's Talimogene Laherparepvec

    Benzinga
  34. Dan Loeb Offers Mea Culpa For 'Mediocre' Returns

    Benzinga
  35. Dan Loeb Fourth Quarter Investor Letter

    GuruFocus
  36. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  37. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  38. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD
  39. Nuveen's Bob Doll Runs Several Top Funds

    IBD
  40. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  41. Credit Suisse Sees Solid Q4 For Amgen

    Benzinga
  42. Amgen Q4 earnings top views

    IBD
  43. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  44. Making Money With Charles Payne: 01/27/15

    FoxBusiness
  45. Amgen Beats Q4 Expectations

    Benzinga
  46. Stocks Weaken Late; Apple Jumps After Hours

    IBD
  47. Earnings Scheduled For January 27, 2015

    Benzinga
  48. 5 Big Biotech Earnings Releases To Watch This Week

    Benzinga
  49. Can CAR-T Therapy Live Up To The Biotech IPO Hype?

    IBD
  50. New Guru Jana Partners' Newest Stock Buys

    GuruFocus
  51. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  52. Cholesterol Drug Costs Eyed

    IBD
  53. Amgen's Decline May Be Linked To Comments Of Express Script's ...

    Benzinga
  54. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  55. Regeneron rises on drug data

    IBD
  56. Crude Awakening As Energy Squeezes Overall Q4 Profit

    IBD
  57. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  58. Drugs May Be Blockbusters

    IBD
  59. Weekly Review Shows Five Industries Gain In December

    IBD
  60. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  61. Pharmaceutical Companies Amgen and Kite Partner for Cancer Therapy

    GuruFocus
  62. Kite Pharma Gets Stock Price Increase Post Amgen Deal

    IBD
  63. UPDATE: Barclays Initiates Coverage On Amgen

    Benzinga
  64. Amgen, Kite Reach Cell Deal

    IBD
  65. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  66. Morgan Stanley Issues Wave Of Pharma & Medical Device Upgrades, ...

    Benzinga
  67. Kite Pharma Up On Amgen Cancer Parternship

    IBD
  68. Stocks Drop 1% In Rising Volume; Visa Falls 1%

    IBD
  69. Morning Market Losers

    Benzinga
  70. Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm ...

    Benzinga
  71. Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy ...

    Benzinga
  72. Nasdaq, Russell 2000 Join New-High Party; GoPro Up Again

    IBD
  73. Tesla Motors Up On Battery News; Stocks At Record

    IBD
  74. Biotech Stocks Take A Beating, But Find Support

    IBD
  75. Are There Any Winners Left In The Biotech Space?

    Benzinga
  76. Indexes Turn Mixed On Data; Celgene Dives

    IBD
  77. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  78. Stocks Struggle To Hold Gains; Alaska Air, Spirit Up

    IBD
  79. Meet 5 Big Tech Stocks Expected To See Profits Surge

    IBD
  80. Amgen Just Crashed 50% In Premarket, Here's How It Looked

    Benzinga
  81. Druckenmiller Adds Healthcare Stocks to Portfolio

    GuruFocus
  82. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  83. How Can Drugmakers Handle New Pricing Pressures?

    IBD
  84. Gilead Sciences Bucks Trend In Biotech Short Interest

    Benzinga
  85. 3 Biotech ETFs Rally On Merger News

    Benzinga
  86. New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec ...

    Benzinga
  87. Hot Drugmakers Build More Labs, Grab Space In Boston

    IBD
  88. Large-Blend Funds Take The Lead For Year-To-Date Total Returns

    Benzinga
  89. A Look At 3 Overbought ETFs

    Benzinga
  90. Big CEOs Are Less Upbeat, But Plan To Hire More

    IBD
  91. Endonovo Therapeutics Receives Final Commissioned Report Recommendations ...

    GuruFocus
  92. Meet 5 Top Drug Stocks That Are Bolting Past Market

    IBD
  93. AMGEN

    IBD
  94. #PreMarket Primer: Tuesday, November 25: Violent Protests In ...

    Benzinga
  95. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus
  96. Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies ...

    Benzinga
  97. #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates ...

    Benzinga
  98. Merck Drug Works: Vytorin Study Proves Successful

    IBD
  99. Events for the Week of Nov. 17-21, 2014

    Benzinga
  100. Amgen Shares Consolidating Ahead Of More Gains?

    Benzinga
Trading Center